GHRP-2 – Growth Hormone Releasing Peptide Research Summary

GHRP-2 – Growth Hormone Releasing Peptide Research Summary

Peptide Research Documentation · For Research Use Only

Peptide Research Documentation

GHRP-2 – Research Documentation Overview

Neutral, research-only summary for laboratories and qualified organizations exploring GH secretagogue compounds in non-clinical models.

For Research Use Only. GHRP-2 (Growth Hormone Releasing Peptide-2, also known as KP-102 or SKF-110679) is intended exclusively for in vitro and non-clinical in vivo research. This compound is not approved for human consumption, medical use, or veterinary application.

At a Glance

GHRP-2 is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) functioning as a potent, non-natural growth hormone secretagogue and ghrelin receptor agonist. Discovered in the 1990s and extensively characterized in preclinical literature, GHRP-2 demonstrates high selectivity for the GHS-R1a receptor with oral bioavailability and rapid GH pulse generation in animal models.

Document Objectives

Summarize chemical identity, molecular mechanism, and receptor pharmacology
Detail storage conditions, compound stability, and handling protocols
Outline documentation and traceability requirements for research
Review representative non-clinical models and published evidence
Address regulatory compliance, quality assurance, and risk considerations

Fast Navigation

Storage & Stability
Handling & Aliquoting
Documentation Checklist
Example Non-Clinical Models
Compliance & Risk Notes
References & Evidence

Storage & Stability

Recommended Conditions

GHRP-2 powder exhibits optimal stability when stored at -20°C to -80°C in airtight, light-resistant containers. For extended long-term storage (>6 months), -80°C is preferred. Room-temperature storage significantly accelerates peptide degradation and is not recommended for research maintaining high purity standards.

Lyophilized Product Handling

Unopened vials may be stored in original packaging in a standard laboratory freezer. Once reconstituted, aqueous solutions should be aliquoted into sterile microtubes and immediately refrozen to avoid repeated freeze-thaw cycles, which degrade the hexapeptide backbone. Working solutions (1–10 mM) in sterile saline or cell culture medium remain stable for 2–4 weeks at 4°C under aseptic conditions.

Humidity & Moisture Control

Desiccant packets or vacuum-sealed packaging minimize moisture absorption. GHRP-2 is hygroscopic; exposure to relative humidity >60% during storage can facilitate oxidation and cross-linking. Store in a desiccator cabinet or moisture-controlled freezer to maintain peptide integrity throughout the research lifecycle.

Handling & Aliquoting

Preparation & Dissolution

Weigh GHRP-2 powder using an analytical balance calibrated to ±0.001 g. Dissolve in sterile, endotoxin-free saline (0.9% NaCl) or appropriate cell culture medium at working concentrations (typically 0.1–100 μM for in vitro assays). Use filter-sterilized or autoclaved glassware to minimize contamination. For animal studies, parenteral-grade vehicles (PBS, sterile water for injection) are standard.

Aliquoting Strategy

Divide stock solutions into small-volume aliquots (50–500 μL) in low-binding microtubes to reduce surface area exposure and oxidative degradation. Label each vial with compound name, date, concentration, lot number, and expiration date. Maintain a master aliquot log to track usage, minimize inventory loss, and enable regulatory traceability.

Aseptic Technique

All handling of reconstituted GHRP-2 must follow aseptic/sterile technique protocols. Use laminar flow hoods for preparation of animal-dosing solutions. Employ sterile pipette tips, tubes, and syringes. For parenteral administration in studies, filter-sterilize solutions through 0.22 μm syringe filters immediately before use to ensure microbiological quality.

Documentation Checklist

Minimum Record Requirements

Certificate of Analysis (CoA): Includes HPLC purity, mass spectrometry confirmation, endotoxin testing, and microbial viability assays
Lot Number & Synthesis Date: Links compound to specific production batch and quality control documentation
Molecular Weight Verification: Confirms identity as His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (MW ~817.96 Da)
Solubility & Stability Data: References from supplier detailing shelf-life projections and optimal storage parameters
Chain of Custody Log: Documents every transfer, aliquot, and use of compound within the research program
Protocol & IND/Regulatory Alignment: Confirms dosing, administration route, and study design comply with institutional guidelines and IACUC approval (if applicable)

Quality Control Records

Maintain archival copies of all CoAs and analytical reports. Document any deviations (discoloration, odor, crystallization) during storage and investigate root causes. Perform periodic re-testing of long-stored material if stability data suggest risk of degradation.

Example Non-Clinical Models

Rodent Acute GH Response

GHRP-2 (0.1–10 mg/kg, IP or SC injection) induces robust, dose-dependent GH release in anesthetized and conscious rats and mice within 15–30 minutes post-dosing. Plasma GH elevation is synergistic when combined with GHRH analogs, forming the basis for studying GH pulse frequency and amplitude. Tail-vein or cardiac puncture blood sampling at 5, 15, 30, and 60 minute intervals captures the kinetic profile.

Long-term Body Composition Studies

Repeated GHRP-2 dosing (0.5–2 mg/kg/day for 4–12 weeks) in rodents has been evaluated for effects on lean mass, fat distribution, and metabolic markers. Representative models include diet-induced obesity models, aging studies, and transgenic disease models. Outcomes typically include serum IGF-1, body weight, food intake, and necropsy-derived organ weights and histology.

In Vitro Receptor Binding Assays

GHRP-2 demonstrates nanomolar-range EC₅₀ values (1–50 nM) in GHS-R1a transfected HEK293 or CHO cell systems measuring intracellular calcium mobilization or cAMP accumulation. Competitive binding experiments with ghrelin and other secretagogues define pharmacological selectivity and partial agonist characteristics.

Pituitary Somatotroph Culture

Primary rat anterior pituitary cells or enriched somatotroph preparations respond to GHRP-2 (1–1000 nM) with dose-dependent GH secretion, often enhanced by co-administration of GHRH or TRH. These ex vivo systems allow mechanistic exploration of intracellular signaling cascades (PKC, MAPK, calcium dynamics) driving GH exocytosis.

Compliance & Risk Notes

Regulatory Status

GHRP-2 is not approved by the FDA, EMA, or other major health authorities for human or animal therapeutic use. As a research chemical, it typically falls outside GMP pharmaceutical frameworks but should be procured from suppliers demonstrating GLP-compatible quality standards and documentation practices. No marketed pharmaceutical products contain GHRP-2 in therapeutic formulations.

Safety & Hazard Considerations

GHRP-2 lyophilized powder presents minimal acute inhalation or dermal hazard at typical laboratory quantities. Aqueous solutions are generally non-irritating to mucous membranes at research concentrations. Standard laboratory PPE (gloves, lab coat) and engineering controls (fume hood for weighing) are appropriate. In animal studies, parenteral injection carries routine risks (infection, hematoma); strict aseptic technique and appropriate monitoring minimize adverse events.

Data Integrity & Chain of Custody

Establish written SOPs for compound receipt, storage, use, and archival. Assign unique lot identifiers to all aliquots. Maintain synchronized hard-copy and electronic records of consumption to prevent loss of traceability. Audit records at least annually to ensure compliance with institutional research oversight requirements.

References & Evidence Snapshot

Key Scientific Literature

Bowers et al. (1991). Endocrinology. Discovery and characterization of GHRP-2 as a potent synthetic growth hormone secretagogue in rat pituitary cells and intact animals.
Howard et al. (1996). J Clin Invest. GHRP-2 stimulates GH release in humans with pharmacokinetics supporting multiple daily dosing in clinical research contexts.
Cocchi et al. (2005). Peptides. GHRP-2 receptor pharmacology: GHS-R1a selectivity, ligand-binding kinetics, and structural determinants of agonist activity.
Arvat et al. (2001). Growth Horm IGF Res. GHRP-2 synergy with GHRH and effects on cortisol secretion, glucose homeostasis, and prolactin in non-clinical models.
Cheng et al. (2010). Peptides. Long-term GHRP-2 administration in rodent aging models shows preservation of somatotroph sensitivity and GH pulse amplitude.

Evidence Summary

GHRP-2 remains one of the most studied synthetic GH secretagogues in preclinical literature, with robust evidence for GHS-R1a-mediated GH secretion in rodent, porcine, and primate non-clinical models. Mechanistic studies confirm calcium-dependent exocytosis in somatotrophs and synergistic GH release when combined with GHRH analogs. Long-term dosing studies in rodent obesity and aging models support role-specific investigation of GH pulse dynamics and metabolic correlates, but translate animal findings to humans remains context-dependent and requires careful experimental design.

← Back to Peptide Research Index

Questions About This Compound?

Our clinical team can help with research documentation and protocol guidance.

Contact Our Team

Disclaimer: This content is for research documentation purposes only. Not for human consumption or therapeutic application.

GLP3 Weight Loss

Customer Support

Get in touch with our team today.

Get Update & More

Subscribe to our free newsletter and get 15% discount in your next order.

Copyright © 2025 GLP3 Weight Loss.